stockrowHims & Hers Health, Inc. (HIMS) vs Kiniksa Pharmaceuticals International, plc (KNSA)
- Hims & Hers Health, Inc. HIMS 24.11 −9.56%
- Kiniksa Pharmaceuticals International, plc KNSA 88.50 −7.93%
Hims & Hers Health, Inc. and Kiniksa Pharmaceuticals International, plc are both Drug Manufacturers Specialty & Generic companies. Kiniksa Pharmaceuticals International, plc is the larger, with a market value of $6.9B against $5.6B — 1.2× the size. Hims & Hers Health, Inc. has negative trailing earnings, so its P/E is not meaningful; Kiniksa Pharmaceuticals International, plc trades at 62.1×. Kiniksa Pharmaceuticals International, plc grew revenue faster over the last twelve months: 58.2% against 28.0%. Kiniksa Pharmaceuticals International, plc has the higher net margin (11.6% vs −5.51%) and the higher return on invested capital (57.7% vs −11.4%). Across the 18 metrics below, Kiniksa Pharmaceuticals International, plc leads on 16 and Hims & Hers Health, Inc. on 2.
Valuation
Profitability
| Metric | HIMS | KNSA | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 68.43% | 90.16% | 53.51% |
| Operating margin | (5.99%) | 13.79% | 0.00% |
| Net margin | (5.51%) | 11.58% | (2.45%) |
| Free cash flow margin | 3.22% | 20.85% | 0.00% |
| Return on equity | (32.03%) | 17.59% | (0.80%) |
| Return on assets | (5.16%) | 12.92% | (1.67%) |
| Return on invested capital | (11.38%) | 57.65% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack